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Abstract
Introduction:  Nasal  polyposis  is  often  found  in  patients  with  cystic  ﬁbrosis.
Objective:  To  assess  the  incidence  of  nasal  polyposis,  the  response  to  medical  treatment,  recur-
rence and  the  need  for  surgical  intervention  in  children  and  adolescents  with  cystic  ﬁbrosis
during a  three-year  follow-up.
Methods:  Clinical  symptoms  (pulmonary,  pancreatic  insufﬁciency,  malnutrition,  nasal  obstruc-
tion), two  positive  sweat  chloride  tests,  and  genotype  ﬁndings  in  23  patients  with  cystic  ﬁbrosis
were analyzed.  All  patients  underwent  nasal  endoscopy  every  12  months  from  January  2005
to December  2007,  to  assess  the  presence  and  grade  of  Nasal  Polyps.  Nasal  polyposis,  when
present, were  treated  with  topical  corticosteroids  for  6--12  months,  with  progress  being  eval-
uated within  the  3  years  of  follow-up.
Results:  In  the  ﬁrst  evaluation,  nasal  polyposis  was  diagnosed  in  30.43%  of  patients  (3  bilateral
and 4  unilateral),  recurrent  pneumonia  in  82.6%,  pancreatic  insufﬁciency  in  87%,  and  malnu-
trition in  74%.  The  presence  of  nasal  polyposis  was  not  associated  with  chloride  values  in  the
sweat, genotype,  clinical  signs  of  severity  of  cystic  ﬁbrosis,  or  nasal  symptoms.  In  the  three-year
period of  follow  up,  13  patients  (56.52%)  had  at  least  one  event  of  polyposis,  with  the  youngest
being diagnosed  at  32  months  of  age.  Only  one  patient  underwent  surgery  (polypectomy),  and
there was  one  diagnosis  of  nasopharyngeal  carcinoma. Please cite this article as: Weber SA, Iyomasa RM, Corrêa CC, Florentino WNM, Ferrari GF. Nasal polyposis in cystic ﬁbrosis: follow-up of
children and adolescents for a 3-year period. Braz J Otorhinolaryngol. 2016. http://dx.doi.org/10.1016/j.bjorl.2016.09.005
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Conclusion:  The  study  showed  a  high  incidence  of  nasal  polyposis.  Monitoring  through  routine
endoscopy  in  patients  with  cystic  ﬁbrosis,  even  in  the  absence  of  nasal  symptoms,  is  highly  rec-
ommended.  The  therapy  with  topical  corticosteroids  achieved  good  results.  Thus,  an  interaction
between pediatricians  and  otolaryngologists  is  necessary.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license  (http://
creativecommons.org/licenses/by/4.0/).
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Polipose  nasal  em  ﬁbrose  cística:  seguimento  em  crianc¸as e  adolescentes  durante  um
período  de  3  anos
Resumo
Introduc¸ão:  A  polipose  nasal  é  frequentemente  encontrada  em  pacientes  portadores  de  Fibrose
Cística.
Objetivo: Avaliar  a  incidência  de  Polipose  Nasal,  a  resposta  ao  tratamento  clínico,  a  recorrência
e a  necessidade  de  intervenc¸ão  cirúrgica  em  crianc¸as  e  adolescentes  com  Fibrose  Cística  durante
um seguimento  de  3  anos.
Método:  Os  sintomas  clínicos  (pulmonar,  insuﬁciência  pancreática,  desnutric¸ão,  obstruc¸ão
nasal),  duas  pesquisas  de  cloro  no  suor  positivas  e  genótipo  de  23  pacientes  com  ﬁbrose  cís-
tica foram  descritos.  Todos  os  pacientes  foram  submetidos  à  endoscopia  nasal  a  cada  12  meses
durante  o  período  de  janeiro  de  2005  a  dezembro  de  2007,  para  avaliac¸ão  de  presenc¸a  e  grau
de Polipose  Nasal.  A  Polipose  Nasal,  quando  presente,  foi  tratada  com  corticosteroide  tópico
de 6  a  12  meses,  e  avaliada  a  evoluc¸ão  nos  3  anos  de  seguimento.
Resultados:  Na  primeira  avaliac¸ão,  a  Polipose  Nasal  foi  diagnosticada  em  30,43%  dos  pacientes
(3 bilaterais  e  4  unilaterais),  pneumonia  recorrente  em  82,6%,  insuﬁciência  pancreática  em  87%
e a  desnutric¸ão  em  74%.  A  presenc¸a  de  Polipose  Nasal  não  se  associou  aos  valores  de  cloro  no
suor, genótipo,  sinais  clínicos  de  gravidade  da  Fibrose  Cística  ou  sintomas  nasais.  Nos  3  anos  de
seguimento,  13  pacientes  (56,52%)  apresentaram  pelo  menos  um  evento  de  Polipose,  sendo  o
mais jovem  diagnosticado  aos  32  meses  de  idade.  Apenas  um  paciente  foi  submetido  à  cirurgia
(polipectomia),  e  houve  um  diagnóstico  de  carcinoma  da  nasofaringe.
Conclusão:  O  estudo  mostrou  alta  incidência  de  Polipose  Nasal.  O  acompanhamento  por  meio
de exames  endoscópicos  de  rotina  em  pacientes  ﬁbrocisticos,  mesmo  na  ausência  de  sintomas
nasais, é  altamente  recomendado.  A  terapia  com  corticoide  tópico  mostrou  bons  resultados.
Sendo assim,  faz-se  necessária  a  interac¸ão  entre  pediatras  e  otorrinolaringologistas.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
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ystic  ﬁbrosis  (CF)  is  an  autosomal  recessive  disease  that
ffects  the  exocrine  glands,  involving  multiple  organs  and
rogressing  chronically  and  progressively.  It  is  the  most  com-
on  lethal  genetic  disease  in  Caucasians,  with  an  average
requency  of  1:2000  live  births.1,2 In  Brazil,  studies  have
evealed  an  incidence  of  1:9500  live  births  in  the  state  of
arana,3 1:8700  in  Santa  Catarina4 and.  1:10,000  in  Minas
erais.5
Respiratory  infections  leading  to  ultimate  respiratory
ailure  are  the  leading  causes  of  death  in  CF  patients.  How-
ver,  mortality  has  been  reduced  in  recent  years  due  to
arlier  diagnosis,  greater  attention  to  prophylaxis  of  recur-
ent  airway  infections,  and  better  control  of  patients  in
pecialized  services.1,2
CF  diagnosis  is  based  on  clinical  and  laboratorial
riteria:  family  history  of  CF,  pancreatic  insufﬁ-
ient/pancreatic  sufﬁcient,  chronic  obstructive  suppurative
A
N
hung  disease,  and  two  high  sweat  chloride  tests  (>60  mEq/L)
nd/or  detection  of  genetic  mutations  described  in
F.  Other  clinical  data  that  suggest  the  disease  are:
econium  ileus  and/or  intestinal  atresia,  hyponatremic
ehydration,  edema  and  hypoalbuminemia,  chronic
anrhinosinusitis,  nasal  polyposis  (NP),  volvulus,  intus-
usception,  bronchiectasis  of  unknown  etiology,  and
zoospermia.6,7
Upper  airway  (UAW)  impairment  such  as  recurrent
inorhinosinusitis,  rhinitis  and/or  NP  occurs  in  over  90%  of
atients.8--16 The  incidence  of  NP,  in  particular,  has  been
eported  in  6--48%  patients,17,18 and  is  symptomatic  in  about
%  patients  at  diagnosis  of  CF.8,10,11,19 The  literature  esti-
ates  that  14%  of  patients  require  surgical  treatment  of
P.8,10,11,19To  date,  the  pathophysiology  of  NP  is  still  unknown.20,21
llergic  processes  have  been  reported  as  a  possible  cause  of
P,  but  the  prevalence  of  atopy  in  patients  with  CF  is  not
igher  than  in  the  general  population.22
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Three-year  follow-up  of  nasal  polyposis  with  cystic  ﬁbrosis  
According  to  data  from  the  literature  and  the  study
previously  conducted  in  our  service,23 a  need  for  better
characterization  of  the  evolution  of  UAW  involvement  in
these  patients  was  identiﬁed.
Thus,  the  aim  of  this  study  was  to  evaluate,  in  the
medium  term,  the  incidence  of  NP,  the  response  to  medical
treatment,  the  rate  of  recurrence,  and  the  need  for  surgi-
cal  intervention  in  children  and  adolescents  with  CF  during
a  3-year  follow  up  period.
Casuistics and methods
The  prospective  cohort  study  was  approved  by  the  Research
Ethics  Committee  of  the  institution  involved  in  this  research.
Parents/caregivers  and  children  over  10  years  signed  a  free
and  informed  consent.
The  initial  sample  consisted  of  23  patients  (20  males),
aged  1  year  and  9  months  to  22  years  and  8  months,
followed  at  the  Cystic  Fibrosis  Reference  Center  of  Pedi-
atrics  Pneumology  Department  of  the  institution  concerned.
Epidemiological  data  (age,  gender)  and  clinical  symptoms
of  CF  were  obtained,  such  as  meconium  ileus,  malnutri-
tion,  pancreatic  insufﬁciency,  recurrent  pneumonia  and/or
other  respiratory  symptoms,  as  well  as  the  conﬁrmation
of  CF  through  sweat  chloride  test7 and  genetic  studies.
All  patients  were  investigated  for  complaints  of  nasal
obstruction,  mouth  breathing,  asthma  and  rhinosinusitis,
and  underwent  nasal  endoscopy  every  12  months  for  3  years.
Nasoﬁbroscopic  procedures  were  performed  under  topical
anesthesia  with  lidocaine  spray  with  no  vasoconstrictor.  In
children  under  3  years  of  age  the  ﬂexible  pediatric  nasoﬁ-
broscope  was  used  (Karl  Storz,  diameter  2.4  mm),  and  in  the
others  the  rigid  nasal  endoscope  (Karl  Storz,  30◦,  diameter
of  2.4  or  4  mm)  was  used.
The  presence  or  absence  of  polyps  was  described,  accord-
ing  to  the  classiﬁcation  suggested  by  Lund  and  Kennedy,24 in
Grade  0  --  no  polyp,  Grade  I  --  polyp  in  the  middle  meatus,
Grade  II  --  polyp  through  the  middle  turbinate,  Grade  III  --
polyp  ﬁlling  the  entire  nasal  cavity.  During  endoscopy,  the
presence  and  color  of  secretion,  and  nasal  mucosa  aspect
(coloration,  edema,  degeneration)  were  evaluated.
Patients  diagnosed  with  NP  underwent  treatment  with
nasal  topic  corticosteroid  for  six  months,  and  were  reeval-
uated  by  endoscopy  after  this  period.  In  case  of  persistent
Polyposis,  patients  were  evaluated  with  computed  tomogra-
phy  of  the  paranasal  sinuses  for  a  possible  surgical  schedule.
In  the  statistical  analysis,  demographic  and  symptoms
data  were  registered  as  mean  and  standard  deviation.  The
association  between  the  presence  of  polyps  and  age,  sex,
clinical  symptoms  and  genetic  mutations  was  assessed  by
Fisher’s  exact  test,  considering  signiﬁcant  p  <  0.05.
Results
CF  diagnosis  was  conﬁrmed  in  all  subjects  through  the
sweat  test.  Genetic  mutations,  using  a  panel  containing
12  mutations,  were  investigated  in  all  patients,  and  in  8
patients  mutations  were  detected:    F  508/other,  three
  F508/ F508,  one    F508/G  542X,  one  G542X/other,
one  R1162X/R1162X,  and  in  9  patients  the  mutation  could
not  be  determined.  A  signiﬁcant  proportion  of  patients
c
p
migure  1  Image  of  endoscopy  of  a  grade  I  polyp  in  the  right
asal cavity  of  patient  no.  12  (P,  polyp;  CM,  middle  turbinate).
ad  clinical  manifestations,  including  recurrent  pneumonia
82.6%),  pancreatic  insufﬁciency  (87%),  malnutrition  (74%)
nd  meconium  ileus  (13%).
The  reported  respiratory  complaints  at  baseline  were
sthma  in  35%  of  patients,  rhinosinusitis  in  22%,  and  preva-
ence  of  oral  breathing  found  in  22%.
In  the  ﬁrst  evaluation  through  nasal  endoscopy,  Nasal
olyps  were  found  in  7  patients  (30.43%).  Of  these,  3  had
ilateral,  and  4  unilateral  NP,  with  Grade  I  in  3  patients,
rade  II  in  1  patient,  and  Grade  III  in  3 patients.  No  associa-
ion  was  found  between  NP,  gender,  age,  clinical  severity,
r  genetic  mutation.  Fig.  1  illustrates  the  results  of  the
ndoscopic  evaluation  (Table  1).
During  the  3  years  of  follow  up,  13  patients  (56.52%)
xperienced  at  least  one  event  of  NP,  with  the  youngest
eing  diagnosed  at  32  months  of  age.  In  these  subjects  the
resence  of  nasal  polyposis  was  not  associated  with  nasal
ymptoms,  such  as  nasal  obstruction,  rhinorrhea  or  mouth
reathing.  At  the  ﬁnal  endoscopy,  six  patients  had  polypo-
is.  In  all  patients,  the  staging  of  polyposis  was  Grade  I,
ndicating  lesser  severity  (p  <  0.05).
The  treatment  of  NP  was  nasal  topic  corticosteroid  at
he  usual  dose,  and  57.14%  of  patients  responded  to  medi-
al  therapy  in  the  subsequent  evaluation,  with  only  one
atient  who  had  bilateral  NP  Grade  III  not  showing  satisfac-
ory  improvement,  and  for  whom  nasal  endoscopic  surgery
as  recommended.  In  these  three  years,  two  patients  died,
nd  one  developed  nasopharyngeal  carcinoma,  undergoing
hemotherapy  and  radiotherapy  with  a  good  response.  The
ndings  regarding  the  3  years  of  follow-up  are  shown  in
able  2.
iscussion
F  patients’  follow-up  in  a  Reference  Center  is  crucial  due
o  the  detection  of  complications,  and  the  possibility  of
ecision-making  by  a  multidisciplinary  team  in  this  service.The  patients  evaluated  in  this  study  showed  classi-
al  clinical  manifestations  of  CF,  such  as  meconium  ileus,
ancreatic  insufﬁciency,  malnutrition,  and  recurrent  pneu-
onia.  All  patients  had  diagnostic  conﬁrmation  supported
A
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Table  1  Results  of  endoscopy  in  patients  with  cystic  ﬁbrosis  and  nasal  polyposis  at  baseline  evaluation,  ﬁrst,  second  and  third  year  of  follow-up.
Pat  Gender  Age  Baseline  evaluation  Evaluation  1st  year  of
follow-up
Evaluation  2nd  year  of
follow-up
Evaluation  3rd  year  of
follow-up
Behavior
01  F  3  y  8  m  No  polyposis  No  polyposis  No  polyposis  No  polyposis
02 M  8  y  7  m  POLYPOSIS  (D  --  Grade
III/E  --  Grade  III)
POLYPOSIS  (R  --  Grade
III/L  --  Grade  II)
No  polyposis
(postsurgery)
No  polyposis  Surgery  deﬁned  on  the
2nd  year  of  follow-up
03 M  6  y  4  m  No  polyposis  No  polyposis  Death  --
04 M  16  y  4  m  No  polyposis  POLYPOSIS  (L  --  Grade  I)  No  polyposis  POLYPOSIS  (L  --  Grade  I)  Topic  nasal
corticosteroid
05 M  2  y  4  m  No  polyposis  No  polyposis  POLYPOSIS  (R  --  Grade
I/L  --  Grade  II)
POLYPOSIS  (R  --  Grade  II)  Topic  nasal
corticosteroid
06 M  2  y  9  m  No  polyposis  POLYPOSIS  (R  --  Grade  I)  POLYPOSIS  (R  --  Grade  I)  POLYPOSIS  (R  --  Grade  I)  Topic  nasal
corticosteroid
07 M  16  y  2  m  No  polyposis  No  polyposis  No  polyposis  No  polyposis
08 M  3  y  9  m  No  polyposis  No  polyposis  No  polyposis  No  polyposis
09 M  5  y  1  m  No  polyposis  No  polyposis  POLYPOSIS  (R  --  Grade  I)  POLYPOSIS  (L  --  Grade  II)  Topic  nasal
corticosteroid
10 M  3  y  1  m  No  polyposis  No  polyposis  No  polyposis  No  polyposis
11 M  4  y  7  m  No  polyposis  POLYPOSIS  (R  --  Grade  I)  POLYPOSIS  (R  --  Grade  I)  POLYPOSIS  (R  --  Grade
I/E  --  Grade  I)
Topic  nasal
corticosteroid
12 M  8  y  6  m  POLYPOSIS  (D  --  Grade  II)  No  polyposis  No  polyposis  No  polyposis  Topic  nasal
corticosteroid
13 M  3  y  9  m  No  polyposis  POLYPOSIS  (L  --  Grade  I)  POLYPOSIS  (L  --  Grade  I)  No  polyposis  Topic  nasal
corticosteroid
14 M  11  y  7  m  POLYPOSIS  (E  --  Grade  I)  No  polyposis  No  polyposis  Death  Topic  nasal
corticosteroid
15 M  6  y  3  m  POLYPOSIS  (D  --  Grade
II/E  --  Grade  III)
No  polyposis  No  polyposis  No  polyposis  Topic  nasal
corticosteroid
16 F  8  y  10  m  POLYPOSIS  (D  --  Grade  I)  POLYPOSIS  (L  --  Grade  I)  No  polyposis  POLYPOSIS  (L  --  Grade  I)  Topic  nasal
corticosteroid
17 M  11  y  7  m  No  polyposis  No  polyposis  No  polyposis  No  polyposis
18 M  22  y  8  m  No  polyposis  No  polyposis  No  polyposis  No  polyposis
19 M  3  y  3  m  POLYPOSIS  (D  -  Grade
III/E  -  Grade  III)
No  polyposis  No  polyposis  No  polyposis  Topic  nasal
corticosteroid
20 M  5  y  4  m  POLYPOSIS  (E  --  Grade  I)  CA  CA  No  polyposis  Topic  nasal  corticos-
teroid  +  chemotherapy
and  radiotherapy
21 M  14  y  11  m  No  polyposis  No  polyposis  No  polyposis  No  polyposis
22 F  13  y  8  m  No  polyposis  No  polyposis  No  polyposis  No  polyposis
23 M  14  y  0  m  No  polyposis  No  polyposis  No  polyposis  No  polyposis
Pat, patient; Age, referent to baseline evaluation; y, years; m, months; R, right; L, left; CA, nasopharynx carcinoma.
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Table  2  Comparison  between  younger  age  with  nasal  polyposis,  number  of  patients  with  nasal  polyposis,  grade  of  polyposis,
unilaterality, presence  of  surgical  indications  and  complications  in  the  baseline  evaluation,  in  the  ﬁrst,  second  and  third  year  of
follow-up.
Baseline  evaluation  1st  year  of  follow-up  2nd  year  of  follow-up  3rd  year  of  follow-up
No.  with  NP  7  6  5  6
NP --  Grade  I  (%)  3  (42.86%)  5  (83.33%)  4  (80%)  4  (66.67%)
NP --  Grade  II  (%)  1  (14.28%)  0  (0%)  1  (20%)  2  (33.33%)
NP --  Grade  III  (%)  3  (42.86%)  1  (16.67%)  0  (0%)  0  (0%)
Unilaterality  4  5  4  5
Surgery 0  1  0  0
Complications  0  Nasopharynx  carcinoma 1  Death 1  Death
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RNP, nasal polyposis; No., number of patients; %, percentage.
by  two  abnormal  chloride  dosages  in  sweat,  according  to  a
standard  method  that  is  supported  by  literature.7
Regarding  the  result  of  the  detection  of  genetic  muta-
tions,  in  52.17%  the  F508  mutation  was  present,  a  high
percentage  of  patients  with  CF  in  Brazil,  despite  the  hetero-
geneity  of  this  population;  this  corroborates  the  literature
that  identiﬁes  the  association  of  this  mutation  with  CF.19 It
should  be  noted  that  there  was  no  correlation  between  the
presence  or  severity  of  NP  and  the  genotype.
In  the  literature,  NP  has  been  reported  with  an  incidence
of  6--48%  in  CF  patients10,11,25 In  this  study,  the  incidence  was
30.43%;  it  was  higher  than  the  one  presented  in  a  national
study  that  reported  the  incidence  to  be  15.2%  in  children
with  a  mean  age  of  9.5  years.26 In  addition,  when  monitoring
CF  patients  over  a  3-year  follow-up,  we  made  the  diagnosis
of  NP  in  a  child  of  2  years  and  8  months,  an  age  younger  than
reported  in  the  literature,  which  describes  the  occurrence
of  NP  only  after  5  years  of  age.27
Even  with  this  study  population  being  predominantly
composed  of  children,  there  was  a  high  incidence  of  NP,
given  that  of  the  13  cases,  12  were  children  (less  than
12  years)  and  only  one  was  a  teenager  of  16  years.  The
literature  brings  the  incidence  of  NP  of  5%  and  15.2%  in
children.26,28
There  was  incidence  of  rhinosinusitis  and  mouth  breath-
ing  in  22%  of  patients,  similar  to  that  found  in  the
literature.9,10,18,29 The  presence  of  NP  did  not  correlate  with
nasal  obstruction  or  secretion.18
Among  patients  with  NP,  3  patients  had  NP  at  baseline
(42.86%),  5  in  1  year  of  follow-up  (83.33%);  4  in  the  2nd
(80%),  and  4  patients  in  the  3rd  year  of  follow-up  (66.67%)
had  small  polyps,  Grade  I,  highlighting  the  importance  of
routine  endoscopic  examination.11 These  data  exceed  the
percentage  found  in  literature  of  68%  of  identiﬁcation  of
small  polyps.18
Only  one  patient  required  surgery  (4.35%),  with  no  recur-
rence  in  the  subsequent  two  years;  the  literature  estimates
the  need  for  surgery  in  patients  with  NP  to  be  20%8,9,11
throughout  life.  Because  of  a  report  of  polyp  recurrence  with
a  need  for  surgery  in  28.57--58%,30,31 these  patients  require
continued  monitoring.
Regarding  the  use  of  topical  corticosteroids,  it  was
observed  that  57.14%  of  patients  responded  satisfactorily  to
the  initial  clinical  treatment,  and  in  a  subsequent  evaluation
there  was  complete  involution  of  the  NP,  which  resembles
the  information  that  there  is  improvement  in  56%  of  patientsith  NP  with  topical  corticosteroids  therapy.8 For  the  pop-
lation  with  CF,  there  is  no  evaluation  data  reporting  the
volution  of  NP  with  clinical  treatment  for  long  periods.
We  believe  that  the  protocol  proposed  by  this  research
roup  of  annual  endoscopic  follow-up  of  CF  patients,  in  addi-
ion  to  clinical  treatment,  may  be  at  least  partly  responsible
or  the  low  need  for  surgical  indication.  CF  is  a  common,
erious  genetic  disease,  but  when  there  is  early  diagnosis
nd  treatment,  comorbidities  are  reduced,  and  the  qual-
ty  of  life  of  these  individuals  improve.  The  limited  number
f  patients  in  this  study  led  to  difﬁculties  in  the  statisti-
al  analysis,  emphasizing  the  importance  of  other  Cystic
ibrosis  Reference  Centers  also  following  this  protocol  and
ublishing  their  results  in  scientiﬁc  settings.
onclusion
he  incidence  of  nasal  polyposis  in  patients  with  cystic  ﬁbro-
is  is  high,  even  among  children,  and  is  not  related  to  the
linical  severity  of  cystic  ﬁbrosis  or  nasal  symptoms.  Rou-
ine  annual  nasal  endoscopy  allows  early  diagnosis  of  nasal
olyps  at  an  early  stage  (Grade  I  polyposis),  and  the  ini-
iation  of  clinical  treatment  with  satisfactory  control  of
he  condition.  Therefore,  the  interaction  between  pulmo-
ologists  and  otolaryngologists  is  crucial  for  the  diagnosis,
reatment  indication,  and  follow-up  of  these  patients.
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